$41.56
1.12% day before yesterday
Nasdaq, Dec 27, 10:00 pm CET
ISIN
US6047491013
Symbol
MIRM
Sector
Industry

Mirum Pharmaceuticals Inc Stock price

$41.56
-5.09 10.91% 1M
+8.45 25.52% 6M
+12.04 40.79% YTD
+11.50 38.26% 1Y
+25.88 165.05% 3Y
+15.66 60.46% 5Y
+28.35 214.61% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.47 1.12%
ISIN
US6047491013
Symbol
MIRM
Sector
Industry

Key metrics

Market capitalization $2.00b
Enterprise Value $2.03b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 6.61
P/S ratio (TTM) P/S ratio 6.50
P/B ratio (TTM) P/B ratio 8.59
Revenue growth (TTM) Revenue growth 112.14%
Revenue (TTM) Revenue $307.03m
EBIT (operating result TTM) EBIT $-93.46m
Free Cash Flow (TTM) Free Cash Flow $-2.20m
Cash position $284.45m
EPS (TTM) EPS $-2.07
P/E forward negative
P/S forward 6.00
EV/Sales forward 6.09
Short interest 16.25%
Show more

Is Mirum Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Mirum Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Mirum Pharmaceuticals Inc forecast:

11x Buy
100%

Analyst Opinions

11 Analysts have issued a Mirum Pharmaceuticals Inc forecast:

Buy
100%

Financial data from Mirum Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
307 307
112% 112%
100%
- Direct Costs 82 82
206% 206%
27%
225 225
91% 91%
73%
- Selling and Administrative Expenses 169 169
41% 41%
55%
- Research and Development Expense 127 127
24% 24%
41%
-70 -70
32% 32%
-23%
- Depreciation and Amortization 23 23
231% 231%
7%
EBIT (Operating Income) EBIT -93 -93
16% 16%
-30%
Net Profit -97 -97
41% 41%
-32%

In millions USD.

Don't miss a Thing! We will send you all news about Mirum Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Mirum Pharmaceuticals Inc Stock News

Positive
Seeking Alpha
4 days ago
Mirum Pharma has three approved products and a promising pipeline, with volixibat showing superior interim data for PBC compared to competitors. It is a buy for volixibat's potential, which is 2-3 years away from approval, but supported in the interim by the other approved drugs. Financially, Mirum has a market cap of $2bn, a cash balance of $294mn, and a cash runway of over 12-15 quarters.
Neutral
Business Wire
18 days ago
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Neutral
Business Wire
about one month ago
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #algs--Mirum Pharmaceuticals to Showcase Data from its LIVMARLI and Volixibat Clinical Programs at AASLD's The Liver Meeting.
More Mirum Pharmaceuticals Inc News

Company Profile

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The firm focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its product candidates include Maralixibat and Volixibat. The company was founded by Niall O'Donnel, Michael Grey and Christopher Peetz on May 7, 2018 and is headquartered in Foster City, CA.

Head office United States
CEO Christopher Peetz
Employees 264
Founded 2018
Website www.mirumpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today